EWPT(SZ:300115)2020-04-28 16:00Financial Performance - Total revenue for Q1 2020 was CNY 1,754,781,810, a slight increase of 0.53% compared to CNY 1,745,495,604 in the same period last year[8]. - Net profit attributable to shareholders was CNY 82,843,577, representing a significant increase of 91.54% from CNY 43,251,222 in the previous year[8]. - Net profit excluding non-recurring gains and losses was CNY 55,569,957, up 52.92% from CNY 36,340,263 in the same period last year[8]. - Basic earnings per share increased to CNY 0.0911, a rise of 90.99% compared to CNY 0.0477 in the same period last year[8]. - Operating revenue for the period reached CNY 1,754.78 million, an increase of 0.53% year-on-year[20]. - Net profit attributable to shareholders increased by CNY 82.84 million, a growth of 91.54% compared to the same period last year[20]. - Net profit for the current period was ¥86,681,416.12, compared to ¥42,068,837.52 in the previous period, indicating a significant growth[60]. Cash Flow and Liquidity - Operating cash flow for the period was CNY 370,846,175, a turnaround from a negative cash flow of CNY -20,224,840 in the previous year[8]. - Cash flow from operating activities was CNY 370,846,174.91, a significant improvement compared to a negative cash flow of CNY -20,224,839.92 in Q1 2019[71]. - Cash inflow from operating activities totaled ¥2,082,884,403.07, compared to ¥1,408,107,527.27 in the previous period, indicating a year-over-year increase of about 47.8%[75]. - Cash outflow from operating activities was ¥1,898,015,413.59, up from ¥1,404,583,221.88, reflecting an increase of approximately 35.2%[75]. - The ending balance of cash and cash equivalents was ¥474,757,387.13, down from ¥551,919,947.65 in the previous period, a decrease of about 14%[78]. - The company reported a cash increase of ¥257,537,483.98 for the current period, compared to an increase of ¥53,748,470.63 in the previous period, indicating a substantial improvement[78]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 9,678,910,789, reflecting a 0.33% increase from CNY 9,646,682,810 at the end of the previous year[8]. - Total current assets reached ¥5,433,067,213.88, showing a slight increase from ¥5,346,846,402.66 at the end of 2019[37]. - Total liabilities decreased to ¥5,119,576,931.60 from ¥5,172,377,958.70, indicating a reduction of approximately 1%[43]. - The company's total equity attributable to shareholders increased to ¥4,343,036,019.05 from ¥4,261,846,199.19, reflecting a growth of approximately 1.9%[46]. Government Support and Investments - The company received government subsidies amounting to CNY 29,979,357 during the reporting period[8]. - The company plans to invest up to USD 5 million in a joint venture in the U.S. for the development and production of medical devices and protective equipment[27]. Operational Adjustments and Strategy - The company reported no significant changes in its strategy or new product developments during the quarter[8]. - The company is actively adjusting its customer and product structure to mitigate risks from U.S.-China trade tensions[20]. Other Income and Expenses - The company experienced a significant increase in other income, which rose by CNY 21.42 million, a growth of 217.43%, mainly due to government subsidies[19]. - Research and development expenses for the quarter were CNY 45,638,758.36, down from CNY 50,215,188.89 in the same period last year[64]. - Financial expenses decreased significantly to CNY 13,374,871.18 from CNY 31,187,650.17 in the previous year[64]. - The company reported a significant increase in other income to CNY 18,575,365.65 compared to CNY 907,725.82 in Q1 2019[64].